+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Naftidrofuryl in chronic arterial disease results of a six month controlled multicenter study using 200 milligram naftidrofuryl tablets



Naftidrofuryl in chronic arterial disease results of a six month controlled multicenter study using 200 milligram naftidrofuryl tablets



Angiology 37(3 Part 1): 160-167



The study was carried out on patients with intermittent claudication (Fontaine's stage II). The arterial and atheromatous origin of the disease was confirmed and localized by angiography or Doppler velocimetry examination. One hundred eight-six patients were selected initially. Their pain-free walking distance on a treadmill (at a speed of 3 km/hour and an inclination of 10%) had to be 150-300 m. During the first month all patients received 3 placebo tablets daily. At the end of this run-in period (D-30; D 0) and after checking walking distinct stability (allowed variation: .+-. 20% between the two measurements) the patients were included in the study. One hundred fifty-four patients were selected and 118 remained during the whole study. The study was designed as a double-blind, using two parallel randomly selected groups. Sixty-four patients received for six months Naftidrofuryl (3 .times. 200 mg tablets daily with meals); 54 patients received placebo under the same conditions. During this period, clinical and paraclinical examinations were carried out every quarter (D 90 and D 180). After checking the initial homogeneity of the Naftidrofuryl and placebo-groups, the comparison between groups indicates a significant improvement in Naftidrofuryl group after 3 and 6 months of treatment. At the end of the study the observed differences in walking distance with Naftidrofuryl are approximately twice the difference in the reference group (D 90: p < 0.05; D 180: p < 0.02). The results of this study indicate that Naftidrofuryl is an efficient pharmacological tool for treatment of patients with chronic arterial disease (Fontaine's stage II).

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 005956045

Download citation: RISBibTeXText


Related references

Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg. Angiology 37(3 Pt 1): 160-167, 1986

Naftidrofuryl in chronic arterial disease. Results of a controlled multicenter study. Angiology 35(11): 701-708, 1984

Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study. Journal of Cardiovascular Pharmacology 16(Suppl. 3): S75, 1990

Naftidrofuryl in arterial occlusive disease. Controlled multicenter double-blind study with oral administration. Deutsche Medizinische Wochenschrift 109(19): 745-750, 1984

A validated HPLC method for the simultaneous determination of naftidrofuryl oxalate and its degradation product (metabolite), naftidrofuryl acid: applications to pharmaceutical tablets and biological samples. Drug Testing and Analysis 5(6): 500-508, 2013

Demonstration of the efficacy of oral naftidrofuryl hydrogen fumarate 300 in arterial occlusive disease in stage ii results of a multicenter double blind study. Vasa Suppl. (20): 365-367, 1987

Naftidrofuryl in the treatment of chronic arterial occlusive disease in the intermittent claudication stage. Vasa Suppl. (20): 361-364, 1987

Naftidrofuryl in the therapy of chronic arterial occlusive disease in the intermittent claudication stage. Vasa. Supplementum 20: 361-364, 1987

Treatment of Stage II Chronic Arterial Disease of the Lower Limbs with the Serotonergic Antagonist Naftidrofuryl. Journal of Cardiovascular Pharmacology 16: S75-S80, 1990

Metabolism studies of naftidrofuryl carbon 14 in animals determination of naftidrofuryl by liquid scintillation in rats auto radiographies of mice. Therapie (London/Paris) 28(2): 281-293, 1974

Effect of oral naftidrofuryl on ischemic stroke recovery in a multicenter, double-blind, placebo-controlled study. Semaine des Hopitaux 74(23-26): 997-1002, Sept 10-24, 1998

Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results of a multicenter, double-blind trial. Clinical Therapeutics 22(7): 834-844, 2000

A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). International Angiology 20(1): 58-65, 2001

Naftidrofuryl in stages III and IV of peripheral arterial occlusive disease. Vasa. Supplementum 24: 38-43, 1988

On the use of naftidrofuryl in stage iii iv of peripheral arterial occlusive disease. Vasa Suppl. (24): 38-43, 1988